

Registration and proxy form

Ordinary General Meeting of BioNTech SE on 25 May 2023



Last name, First name*

Street*

Shareholder number*

ZIP/City*

Number of shares*

* Mandatory fields

Please use one of the registration options below and send the form to the registration address by the registration deadline **on 18 May 2023, 24:00 (CEST)** to BioNTech SE, c/o Computershare Operations Center, 80249 Munich, Germany, Email: anmeldestelle@computershare.de. After registration has been completed, it is still possible to issue a power of attorney and, if necessary, instructions using this form (by mail or e-mail to the above address no later than **Wednesday, 24 May 2023, 24:00 (CEST)** (time of receipt)). Since the form is processed automatically, additional information outside the specified fields cannot be taken into account.

1 Registration

My/our shareholding is hereby registered for the above-mentioned general meeting in one of the following ways.



Power of attorney and instructions to the proxies nominated by the company

I/We authorize the proxies appointed by the company (Dr. Oliver Hennig, Munich und Jan Kürschner, Munich) individually subject to the disclosure of my/our name(s) and with the right to sub-authorize, to represent me/us at the Annual General Meeting of BioNTech SE to be held in Mainz on 25 May 2023 and to exercise the voting rights as marked overleaf under number 3.

Please turn to give instructions. ►



Personal participation

I/We will come to the meeting myself. Please send the confirmation of registration(s) to my/our address stated above.

Note: In the case of a registered joint account, two confirmations of registration will be issued to the joint account holder in as equal shares as possible. If only one co-owner of the joint depository is to attend the meeting, please enter his/her details under item 2. In the case of a registered legal entity, a representative/authorized representative of the legal entity will attend the meeting. The representative's power of representation/authorization will be evidenced separately.



Representation by an authorised party

I/we authorize the person named under number 2 to represent me/us at the Annual General Meeting of BioNTech SE to be held in Mainz on 25 May 2023. The authorization takes place by disclosing the name(s) and includes the exercise of all shareholder rights, including the right to vote and the right to sub-authorize. Voting rights may also be exercised by an association of shareholders. I/we have expressly informed the authorized representative of the information on data protection and the transfer of personal data. A confirmation of registration will be sent to the authorized third party so that they can exercise their voting rights.

2

Information about the authorized person

In this section, please enter the data of the authorized person required for processing.

First name of the authorized representative*

Last name of the authorized representative*

Street*

Number*

Country

ZIP*

Place or registered office of the company*

* Mandatory fields

Signature(s) resp. person(s) making the declaration (legible)

Last name, First name*

Street*

Shareholder number*

ZIP/City*

Number of shares*

* Mandatory fields

3 Issuing instructions

Resolution proposals according to the Federal Gazette (Bundesanzeiger)	Yes	No	Abstain
2. Resolution on the appropriation of the balance sheet profit for the financial year 2021	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Resolution on the appropriation of the balance sheet profit for the financial year 2022	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4. Resolution on the approval of the actions of the Management Board	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. Resolution on the approval of the actions of the Supervisory Board	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Resolution on the appointment of the auditor of the financial statements and the auditor of the consolidated financial statements for the financial year 2023 as well as the auditor for any audit or review of interim financial information during the year	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7. Resolution on the approval of the remuneration report	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8. Resolution on elections to the Supervisory Board			
8.1. Baroness Nicola Blackwood	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8.2. Dr. Ulrich Wandschneider	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8.3. Michael Motschmann	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9. Resolution on the Amendment to Sec. 16 para. 5 of the Articles of Association to authorise the Management Board to provide for the holding of a virtual Annual General Meeting	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10. Resolution on the Amendment to Sec. 16 para. 4 of the Articles of Association on the participation of members of the Supervisory Board in the Annual General Meeting by means of video and audio transmission	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
11. Resolution on the approval of the conclusion of four domination and profit and loss transfer agreements			
11.1. Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and BioNTech Idar-Oberstein Services GmbH as dependent company.....	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
11.2. Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and NT Security and Services GmbH as dependent company	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
11.3. Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and BioNTech BioNTainer Holding GmbH as dependent company	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
11.4. Approval of the conclusion of the domination and profit and loss transfer agreement between the Company as controlling company and BioNTech Individualized mRNA Manufacturing GmbH as dependent company	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

You can cast your votes on properly submitted, admissible counter motions and election proposals in the Investor Portal.